Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children.

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2025-09-20 DOI:10.1111/pde.70043

Aisa Longnecker, Cristina M Foschi, Valerie M Carlberg, Lisa Swanson, Kristen E Holland

引用次数: 0

Abstract

Spesolimab is an IL-36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5-year-old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin-36 receptor antagonist (DITRA) as well as a 6-year-old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.

查看原文本刊更多论文

Spesolimab成功治疗2例幼儿广泛性脓疱性银屑病。

Spesolimab是一种IL-36受体单克隆抗体拮抗剂，被批准用于12岁及以上的广泛性脓疱性银屑病患者。虽然它在这一人群中显示出有希望的结果，但关于斯匹索利单抗在年轻患者中的疗效和剂量的研究文献有限。我们报告1例5岁女性广泛性脓疱性银屑病，其常染色体隐性缺乏白介素-36受体拮抗剂（DITRA），以及1例6岁女性广泛性脓疱性银屑病的遗传状况未知，均成功地用spesolimab治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.